104 related articles for article (PubMed ID: 28972039)
1. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
Zauderer MG; Tsao AS; Dao T; Panageas K; Lai WV; Rimner A; Rusch VW; Adusumilli PS; Ginsberg MS; Gomez D; Rice D; Mehran R; Scheinberg DA; Krug LM
Clin Cancer Res; 2017 Dec; 23(24):7483-7489. PubMed ID: 28972039
[No Abstract] [Full Text] [Related]
2. Clinical Response of Live-Attenuated,
Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.
de Fonseka D; Morley A; Stadon L; Keenan E; Walker S; Smith S; Harvey JE; Cox RA; Dangoor A; Comins C; Rogers C; Edey A; Addeo A; Maskell NA
Trials; 2018 Aug; 19(1):467. PubMed ID: 30157910
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Parikh K; Mandrekar SJ; Allen-Ziegler K; Esplin B; Tan AD; Marchello B; Adjei AA; Molina JR
Oncologist; 2020 Jun; 25(6):523-531. PubMed ID: 31872928
[TBL] [Abstract][Full Text] [Related]
5. UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Haakensen VD; Öjlert ÅK; Thunold S; Farooqi S; Nowak AK; Chin WL; Grundberg O; Szejniuk WM; Cedres S; Sørensen JB; Dalen TS; Lund-Iversen M; Bjaanæs M; Helland Å
Eur J Cancer; 2024 May; 202():113973. PubMed ID: 38447379
[TBL] [Abstract][Full Text] [Related]
6. Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).
Wozniak AJ; Schneider B; Kalemkerian GP; Daly B; Chen W; Ventimiglia J; Nagasaka M; Zauderer MG
Clin Lung Cancer; 2023 Sep; 24(6):563-567. PubMed ID: 37301693
[No Abstract] [Full Text] [Related]
7. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Manning-Geist BL; Gnjatic S; Aghajanian C; Konner J; Kim SH; Sarasohn D; Soldan K; Tew WP; Sarlis NJ; Zamarin D; Kravetz S; Laface I; Rasalan-Ho T; Qi J; Wong P; Sabbatini PJ; O'Cearbhaill RE
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900251
[TBL] [Abstract][Full Text] [Related]
8. Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms.
Cliff ERS; Kesselheim AS; Feldman WB
J Clin Oncol; 2023 Aug; 41(24):3984-3987. PubMed ID: 37343194
[No Abstract] [Full Text] [Related]
9. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
Watanabe S; Yamaguchi OU; Masumoto AI; Maeno Y; Kawashima Y; Ishimoto O; Sugawara S; Yoshizawa H; Kikuchi T; Nukiwa T; Kobayashi K
Anticancer Res; 2018 Aug; 38(8):4699-4704. PubMed ID: 30061238
[TBL] [Abstract][Full Text] [Related]
11. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation.
Hu M; Wang H; Wang L; Yang M; Lou Y; Jin J
Medicine (Baltimore); 2018 Jul; 97(28):e11374. PubMed ID: 29995776
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.
Vollmers PL; Mundhenke C; Maass N; Bauerschlag D; Kratzenstein S; Röcken C; Schmidt T
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1785-1792. PubMed ID: 29943097
[TBL] [Abstract][Full Text] [Related]
13. Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.
Veronese P; Hachul DT; Scanavacca MI; Hajjar LA; Wu TC; Sacilotto L; Veronese C; Darrieux FCDC
PLoS One; 2018; 13(5):e0196763. PubMed ID: 29723224
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Maj E; Filip-Psurska B; Milczarek M; Psurski M; Kutner A; Wietrzyk J
Int J Oncol; 2018 Feb; 52(2):337-366. PubMed ID: 29345296
[TBL] [Abstract][Full Text] [Related]
15. Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models.
Guo Y; Zeng H; Chang X; Wang C; Cui H
BMC Cancer; 2018 Jan; 18(1):81. PubMed ID: 29338697
[TBL] [Abstract][Full Text] [Related]
16. Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.
Morgan KM; Fischer BS; Lee FY; Shah JJ; Bertino JR; Rosenfeld J; Singh A; Khiabanian H; Pine SR
Mol Cancer Ther; 2017 Dec; 16(12):2759-2769. PubMed ID: 28978720
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
18. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
19. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
Tsao AS; Lindwasser OW; Adjei AA; Adusumilli PS; Beyers ML; Blumenthal GM; Bueno R; Burt BM; Carbone M; Dahlberg SE; de Perrot M; Fennell DA; Friedberg J; Gill RR; Gomez DR; Harpole DH; Hassan R; Hesdorffer M; Hirsch FR; Hmeljak J; Kindler HL; Korn EL; Liu G; Mansfield AS; Nowak AK; Pass HI; Peikert T; Rimner A; Robinson BWS; Rosenzweig KE; Rusch VW; Salgia R; Sepesi B; Simone CB; Sridhara R; Szlosarek P; Taioli E; Tsao MS; Yang H; Zauderer MG; Malik SM
J Thorac Oncol; 2018 Nov; 13(11):1655-1667. PubMed ID: 30266660
[TBL] [Abstract][Full Text] [Related]
20. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Chung HC; Bang YJ; S Fuchs C; Qin SK; Satoh T; Shitara K; Tabernero J; Van Cutsem E; Alsina M; Cao ZA; Lu J; Bhagia P; Shih CS; Janjigian YY
Future Oncol; 2021 Feb; 17(5):491-501. PubMed ID: 33167735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
